INSPIRIS RESILIA aortic valve is a first-of-its-kind resilient ... The stock has gained around 25.6% over the last three months. Align Technology has an expected long-term adjusted earnings ...

This is a significant progress as more and more younger and active patients undergo bioprosthetic aortic valve replacement." Current technologies utilizing this novel tissue include the INSPIRIS ...

It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology ...

“Given that TAVR is mounted on a flexible stent, unlike Inspiris with Resilia tissue mounted on a rigid surgical valve frame, we will need to determine the long-term outcomes of Resilia in a ...

Today, RESILIA tissue is used in a wide range of Edwards’ surgical and transcatheter platforms, including the INSPIRIS RESILIA aortic surgical valve, the KONECT RESILIA aortic surgical valve ...

The win ratio for the second primary end point was 1.17 (95% CI, 0.90 to 1.51; P=0.25). The Kaplan–Meier ... either TAVR with a SAPIEN 3 valve or surgical aortic-valve replacement with a ...

with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's prespecified goal of 25% to show non-inferiority, according to a ...

Current technologies utilizing this novel tissue include the INSPIRIS RESILIA aortic valve, the KONECT RESILIA* aortic valved conduit, the MITRIS RESILIA* mitral valve and the SAPIEN 3 Ultra RESILIA* ...

This is a significant progress as more and more younger and active patients undergo bioprosthetic aortic valve replacement Current technologies utilizing this novel tissue include the INSPIRIS ...